A novel anatomic classification to guide transcatheter aortic valve replacement for pure aortic regurgitation.
anatomic classification
dual-anchoring theory
native aortic regurgitation
transcatheter aortic valve replacement
Journal
Echocardiography (Mount Kisco, N.Y.)
ISSN: 1540-8175
Titre abrégé: Echocardiography
Pays: United States
ID NLM: 8511187
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
25
10
2022
received:
18
09
2022
accepted:
04
11
2022
pubmed:
15
11
2022
medline:
15
12
2022
entrez:
14
11
2022
Statut:
ppublish
Résumé
The success of transcatheter aortic valve replacement (TAVR) in native aortic regurgitation (AR) is limited by the absence of calcified anchoring structures. We sought to evaluate transfemoral TAVR in patients with native AR using a novel aortic root imaging classification. From March to November 2021, 81 patients with severe AR were prospectively enrolled in 2 cardiac centers in China. All were evaluated using multidetector computed tomography (MDCT) and classified into 4 anatomic types in reference to transcatheter heart valve (THV) anchoring: Type 1: anchoring at the left ventricular outflow tract (LVOT), annulus, and ascending aorta (AA); Type 2: anchoring at the annulus and AA; Type 3: anchoring at the annulus and LVOT; and Type 4: anchoring at only 1 level or none at all. Based on the dual-anchoring strategy, patients with Types 1-3 were considered TAVR candidates. Procedural and 30-day outcomes were assessed according to Valve Academic Research Consortium-3 definitions. TAVR was performed in 32 (39.5%) patients (71.9 ± 8.0 years of age, 71.9% were male) using 2 self-expanding THVs. Types 1, 2, and 3 comprised 13 (40.6%), 11 (34.4%), and 8 (25.0%) cases, respectively. The procedural and device success rates were 100% and 93.8%, respectively, with 2 THV migration. Eight patients (25.0%) required a permanent pacemaker, and 2 (6.3%) developed moderate paravalvular leaks. No deaths or other major complications occurred during the study. The novel anatomic classification and dual-anchoring strategy were associated with a high procedural success rate with favorable short-term safety and clinical outcomes.
Sections du résumé
BACKGROUND
The success of transcatheter aortic valve replacement (TAVR) in native aortic regurgitation (AR) is limited by the absence of calcified anchoring structures. We sought to evaluate transfemoral TAVR in patients with native AR using a novel aortic root imaging classification.
METHODS
From March to November 2021, 81 patients with severe AR were prospectively enrolled in 2 cardiac centers in China. All were evaluated using multidetector computed tomography (MDCT) and classified into 4 anatomic types in reference to transcatheter heart valve (THV) anchoring: Type 1: anchoring at the left ventricular outflow tract (LVOT), annulus, and ascending aorta (AA); Type 2: anchoring at the annulus and AA; Type 3: anchoring at the annulus and LVOT; and Type 4: anchoring at only 1 level or none at all. Based on the dual-anchoring strategy, patients with Types 1-3 were considered TAVR candidates. Procedural and 30-day outcomes were assessed according to Valve Academic Research Consortium-3 definitions.
RESULTS
TAVR was performed in 32 (39.5%) patients (71.9 ± 8.0 years of age, 71.9% were male) using 2 self-expanding THVs. Types 1, 2, and 3 comprised 13 (40.6%), 11 (34.4%), and 8 (25.0%) cases, respectively. The procedural and device success rates were 100% and 93.8%, respectively, with 2 THV migration. Eight patients (25.0%) required a permanent pacemaker, and 2 (6.3%) developed moderate paravalvular leaks. No deaths or other major complications occurred during the study.
CONCLUSIONS
The novel anatomic classification and dual-anchoring strategy were associated with a high procedural success rate with favorable short-term safety and clinical outcomes.
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
1571-1580Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632. https://doi.org/10.1093/eurheartj/ehab395
Otto CM, Nishimura RA, Bonow RO, et al. ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, J Am Coll Cardiol. 2021;77(2020):e25-e197. ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Carroll JD, Mack MJ, Vemulapalli S, et al. STS- ACC TVT registry of transcatheter aortic valve replacement, STS-ACC TVT registry of transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76:2492-2516. https://doi.org/10.1016/j.jacc.2020.09.595
Yang Y, Wang Z, Chen Z, et al. Current status and etiology of valvular heart disease in China: a population-based survey. BMC Cardiovasc Disord. 2021;21:339. https://doi.org/10.1186/s12872-021-02154-8
Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on valvular heart disease. Eur Heart J. 2003;24:1231-1243. https://doi.org/10.1016/s0195-668x(03)00201-x
Arora S, Lahewala S, Zuzek Z, et al. Transcatheter aortic valve replacement in aortic regurgitation: the U.S. experience. Catheter Cardiovasc Interv. 2021;98:E153-E162. https://doi.org/10.1002/ccd.29379
Takagi H, Hari Y, Kawai N, Ando T. ALICE (All-Literature Investigation of Cardiovascular Evidence) Group, meta-analysis and meta-regression of transcatheter aortic valve implantation for pure native aortic regurgitation. Heart Lung Circ. 2020;29:729-741. https://doi.org/10.1016/j.hlc.2019.04.012
Testa L, Latib A, Rossi ML, et al. Core, corevalve implantation for severe aortic regurgitation: a multicentre registry. EuroIntervention. 2014;10:739-745. https://doi.org/10.4244/EIJV10I6A127
Roy DA, Schaefer U, Guetta V, et al. Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J Am Coll Cardiol. 2013;61:1577-1584. https://doi.org/10.1016/j.jacc.2013.01.018
Yoon SH, Schmidt T, Bleiziffer S, et al. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J Am Coll Cardiol. 2017;70:2752-2763. https://doi.org/10.1016/j.jacc.2017.10.006
Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30:303-371.
Wang M, Song G, Chen M, et al. Twelve-month outcomes of the TaurusOne(R) Valve for transcatheter aortic valve implantation in patients with severe aortic stenosis. EuroIntervention. 2022;17:1070-1076. https://doi.org/10.4244/EIJ-D-21-00040
Jilaihawi H, Wu Y, Yang Y, et al. Morphological characteristics of severe aortic stenosis in China: imaging corelab observations from the first Chinese transcatheter aortic valve trial. Catheter Cardiovasc Interv. 2015;85(Suppl 1):752-761. https://doi.org/10.1002/ccd.25863
Song G, Jilaihawi H, Wang M, et al. Severe symptomatic bicuspid and tricuspid aortic stenosis in China: characteristics and outcomes of transcatheter aortic valve replacement with the Venus-A Valve, Struct. Heart. 2018;2:60-68. https://doi.org/10.1080/24748706.2017.1398437
Zhou D, Pan W, Wang J, et al. VitaFlow transcatheter valve system in the treatment of severe aortic stenosis: one-year results of a multicenter study. Catheter Cardiovasc Interv. 2020;95:332-338. https://doi.org/10.1002/ccd.28226
Généreux P, Piazza N, Alu MC, et al. Varc-3. Valve Academic Research Consortium. Eur Heart J. 2021;42:1825-1857. https://doi.org/10.1093/eurheartj/ehaa799
Webb JG, Htun N. Transcatheter options for the treatment of noncalcified aortic regurgitation. JACC Cardiovasc Interv. 2015;8:1850-1853. https://doi.org/10.1016/j.jcin.2015.10.004
Franzone A, Piccolo R, Siontis GCM, et al. Transcatheter aortic valve replacement for the treatment of pure native aortic valve regurgitation: a systematic review. JACC Cardiovasc Interv. 2016;9:2308-2317. https://doi.org/10.1016/j.jcin.2016.08.049
Bob-Manuel T, Kadire S, Heckle MR, Wang J, Ibebuogu UN. Outcomes following transcatheter aortic valve replacement in patients with native aortic valve regurgitation. Ann Transl Med. 2018;6:8. https://doi.org/10.21037/atm.2017.09.29
Thielmann M, Tsagakis K, El Gabry M, Jakob H, Wendt D. Transcatheter aortic valve implantation (TAVI) in patients with aortic regurgitation. Ann Cardiothorac Surg. 2017;6:558-560. https://doi.org/10.21037/acs.2017.09.16
Graziani F, Mencarelli E, Burzotta F, et al. Early hemodynamic and structural impact of transcatheter aortic valve replacement in pure aortic regurgitation. JACC Cardiovasc Interv. 2020;13:2582-2584. https://doi.org/10.1016/j.jcin.2020.05.038